May 17, 2019 -- Qiagen is developing a liquid biopsy companion diagnostic for Inovio's investigational VGX-3100 immunotherapy for the nonsurgical treatment of advanced cervical dysplasia associated with the cancer-causing human papillomavirus (HPV).
The test will be used to help predict which patients will benefit from receiving VGX-3100, a DNA-based immunotherapy in phase III development for the treatment of women positive for HPV types 16 and 18, which cause most cervical cancers and high-grade squamous intraepithelial lesions, the two companies said in a joint statement on May 16. Inovio plans to file a biologics license application (BLA) for the drug in the U.S. in 2021.
The agreement on a liquid biopsy companion diagnostic grew out of a partnership to develop novel microRNA biomarkers. Qiagen's digene HC2 high-risk HPV DNA test is approved for use in the U.S. and Canada. Financial terms of the deal were not disclosed.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current